# Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients

> **NCT04164368** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 67 (actual)

## Conditions studied

- Double Expressor Lymphoma

## Interventions

- **DRUG:** Lenalidomide combined with R-CHOP

## Key facts

- **NCT ID:** NCT04164368
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2021-08-09
- **Final completion:** 2023-08-30
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04164368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04164368, "Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04164368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*